Entrada, enGene lose over half their value on clinical readouts

The week’s biggest movers on clinical readouts each lost more than half their value, as enGene’s bladder cancer data tempered earlier efficacy expectations and Entrada’s Duchenne muscular dystrophy readout showed lower-than-expected dystrophin production.

Shares of Engene Holdings Inc. (NASDAQ:ENGN) fell 81% Thursday after updated interim data from the Phase II LEGEND trial showed lower complete response rates for detalimogene voraplasmid than earlier results had suggested...